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Held at Loch Lomond, Scotland under the sponsorship of the Cancer Research Campaign and organised by
the British Association for Cancer Research*
The format of the workshop comprised six separate
topics including a debate, incorporating an
increased element of discussion in addition to
presentations by the invited speakers.
The meeting was initiated by the topic on clinical
cancer therapy with G. McVie (Amsterdam) who
contended that clinical pharmacology is essential in
drug development for cancer therapy. He pointed
out that there is little information on dose response,
schedule-dependent response or drug receptor
interaction in clinical cancer. Expensive human
tumour models such as clonogenic assays and
xenografts are not useful screening tools but should
be used for defining the optimal conditions of drug
action; and examination of the mechanism and site
of action, dose and schedule effect, primary
resistance and secondary resistance characteristics.
Opportunities should be taken in phase I studies to
look at pharmacokinetics as well as toxicity and
response (if any). The ethics of testing new drugs
requires reappraisal, recognising that most so-called
chemosensitive tumours are, in fact, from the
moment of metastasis incurable by conventional
therapy; thus breast cancer, extensive small cell
lung cancer and most ovarian cancer as well as
follicular lymphomas could be used for evaluating
new anticancer drugs. Pharmacodynamic studies
should be included demanding tissue as well as
blood testing. Dr McVie speculated that more
information would come from new techniques, e.g.
nuclear magnetic resonance for some compounds,
possible positron emission scanning for certain
labelled compounds and even monoclonal anti-
bodies directed again the DNA adducts as end
points for the effects of anticancer drugs against
tumour cells. He submitted that the patient is the
*Enquiries to the BACR Secretariat, c/o Institute of
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best model for testing new anticancer compounds
and that animal studies should be used for
exploiting the toxicology and pharmacological
studies. It has also become conventional to use
combination chemotherapy for treating 'drug
sensitive' tumours so that single agent studies are
confined to the well known 'hard nuts' of colon,
pancreas, non-small cell lung cancer and kidney
cancer.
M. Soukop (Glasgow) reviewed the evidence that a
dose response curve for cancer drugs obtained in
clinical experience. There have been relatively few
randomised trials examining dose either in absolute
terms or in terms of dose-rate as a variable for
testing in clinical trials. The narrow range of
therapeutic index means that at best a two-fold
dose alteration is all that can be achieved but dose
reductions have been reported to be associated with
reduced response rate or reduced disease-free
survival. He reviewed the evidence for a dose
response from studies using thiotepa and
methotrexate respectively in lymphoma, and
combination chemotherapy for small cell lung
cancer. To some extent the transplant data for
acute lymphoblastic leukaemia and for lymphomas
provide further supportive evidence. It has also
been hypothesised that chemotherapy is propor-
tionately much more effective against small volume
disease as opposed to advanced disease. It is
therefore predicted that a dose response curve
might be particularly steep in the adjuvant setting.
This idea is possibly supported by adjuvant breast
cancer studies of Bonadonna although these data
and their interpretation have been much criticised
elsewhere. Summarising the programmes employing
intensive therapy, he pointed out that autologous
bone marrow protection allows major dose
escalation for drugs which have bone marrow as
the major limiting toxicity and melphalan, BCNU,
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cyclophosphamide and VP16 have all been
employed at 5-10 fold the conventional doses.
Whilst the results have been encouraging for acute
leukaemia and possibly for lymphoma, the situation
with many other tumours, notably small cell lung
cancer and malignant melanoma, is less impressive
as it is not possible to maintain the necessary dose
rate to maintain remissions which are at present
very short term. He concluded that a dose response
curve in human cancer therapy does exist and that
dose escalation appropriately used will be beneficial
in a limited number of situations.
In a section dealing with antimetabolites J.F. Smyth
(Edinburgh) reviewed the limitations of anti-
metabolites in treating solid tumours. He reiterated
that the limitations of antimetabolites are those of
all cytotoxic drugs in clinical use which is their lack
of selectivity by imposing host toxicity and their
relevant inefficacy in destroying large numbers of
tumour cells either de novo or following a period of
drug exposure resulting in apparently 'acquired'
drug resistance. However, relative to other classes
of cytotoxic drugs there is a wealth of information
regarding the mechanism of action of anti-
metabolites which has led to great optimism for
improving their therapeutic index. With the
development of drug assays to monitor parent
drugs and their metabolites, as well as changes in
host metabolism, it has been possible to explore
the clinical use of these drugs in a wider range of
doses and schedules than with other classes of anti-
cancer drugs. Despite this there has only been a
modest improvement in their therapeutic value.
Identification of key enzyme systems as targets for
the action of the first generation of antimetabolites
such as methotrexate and 5-fluorouracil aided in
the design of second generation drugs but the latter
have not surpassed the limited efficacy of their
predecessors. Enlarging on one of Dr McVie's
points, he stressed the major gaps in our knowledge
of the clinical activity of common antimetabolites.
Despite its use in combination chemotherapy
methotrexate was almost ignored as a single drug
for treating gastrointestinal cancer, basic phase II
type data being virtually non-existent.
A. Jackman (Royal Marsden) presented a paper on
behalf of A.H. Calvert on antimetabolite resistance.
She stressed again the problems of antimetabolite
resistance which is that target enzymes and
alternative substrates can be produced in large
excess to overcome the competitive inhibition
afforded by analogues in cancer cells. Building on
the experience with methotrexate in the clinic and
in vitro as a folate-based inhibitor of thymidylate
synthetase, the compound NIO-propargyl-5, 8-
dideazafolic acid (CB3717) has been synthesised at
the Institute of Cancer Research and used in
clinical trials at the Royal Marsden Hospital and
elsewhere. The compound acts as an in vitro and in
vivo inhibitor of thymidylate synthetase (TS) and its
action can be overcome by thymidine. Interestingly
however, CB3717 resistance which can be induced
in vitro and can be shown to be cross resistant to
other folate-based thymidylate synthetase inhibitors
does not exhibit cross resistance with 5-
fluorodeoxyuridine (FUDR). This was not a
predicted finding but it may be of value in treating
thymidylate synthetase over-producing tumours.
These would be selectively damaged by FUDR
therapy whereas normal tissue (non-amplified for
the production of TS) would be rescued by
thymidine.
L Hart (ICRF) reviewed the development of
heterogeneity for metastatic capacity in animal and
human derived cell lines. He reviewed the work of
Fidler & colleagues on the B16 melanoma model
and went on to talk about human tumour
xenograft models, arriving at the rather alarming
conclusion that anticancer drugs are not only
carcinogenic and mutagenic but might even
facilitate tumour progression by enhancing the
metastatic capability of a tumour. Using their xeno-
graft models and syngeneic mouse tumours they
have shown recently that 5-azacytidine, hydroxy-
urea, methotrexate and cytosine arabinoside can all
increase malignant or metastatic behaviour by
various mechanisms. Moderate dosage can enhance
differentiation status but paradoxically facilitate
metastases; likewise, alterations in DNA
methylation and possible gene amplification may
both be associated with enhanced metastatic
capacity. This may have profound implications for
the treatment of cancers by adjuvant chemotherapy
for the patients whom it fails to cure. It might even
be speculated that it could in part account for the
'catch-up' effect that one sees in the survival curves
of patients on adjuvant chemotherapy who
eventually die from their disease.
D.N. Carney (Dublin) then presented data on clones
of small cell lung cancer which show heterogeneity
in terms of morphology, biochemistry, cell surface
antigen expression (including HLA) and oncogene
expression. Regardless of site of derivation or
treatment status of the patient he said that the
consistent pattern was that 70% of tumours showed
a classical small cell type of growth pattern and
biochemical behaviour, whereas 25% had a variant
growth pattern in terms of morphology, growth in
vitro and biochemical function. A further 4-6%
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into small cell, squamous and adeno-carcinoma. He
suggested there was a crude correlation with the
clinical events in terms of responsiveness and
tumour morphology implying that the variant line
in vitro was a reflection of drug resistant disease in
vivo in small cell cancer. In non small cell lung
cancers endocrine function could be discerned in
vitro in 10-20% of lines and he speculated that this
might well be a further correlation with chemo-
sensitivity in the clinic. This may all support the
view that there is a single stem cell of origin for all
common varieties of lung cancer regardless of
morphology at light microscopy level and one
could regard lung cancer as divisible into endo-
crinologically functional or non-functional tissue
with appropriate implications for chemosensitivity.
K. Tew (Philadelphia) reviewed the role of thiols
and enzymes which conjugate the various drug
species with glutathione as targets for overcoming
in vitro resistance. He pointed out that insufficient
studies have been performed on the glutathione-S-
transferases with too much attention being paid to
glutathione depletion per se. Using the Walker cell
line a prolonged increment in the level of
glutathione-S-transferase as long as 30 days
following single exposure to chlorambucil has
already been demonstrated. The attraction of
looking at the enzymes more carefully is their
distinctive tissue distribution with isoenzymes being
associated with specific tissues and presumably
therefore with tumours arising from specific tissues.
Variation in glutathione-S-transferase function
offers the possibility of specific tissue inhibition as
a new approach for specific tumour depletion with
consequent improved therapeutic index.
P. Workman (Cambridge) reviewed the evidence
that radiosensitising drugs epitomised by mison-
idazole could preferentially enhance the effects of
cytotoxic drugs against cancer cells. He provided
evidence for the preferential activation of
misonidazole in oxygen depeleted areas of
macroscopic cancers and again stressed that there
was a preferential boost of cytotoxic action against
hypoxic as opposed to oxic tumour cells. This gives
a possibility of improving the therapeutic index and
has been demonstrated for CCNU, melphalan and
cyclophosphamide in vivo. He pointed out that
there was little evidence on the efficacy or otherwise
of radiosensitisers for tumours with induced
resistance but reminded the audience that
misonidazole and similar compounds might have
mechanisms of action other than the production of
abnormal DNA or protein adducts as targets in
anoxic cells. There is evidence for changing drug
metabolism and delivery and even thiol levels. New
compounds based on misonidazole but with
reduced neurotoxicity are now being examined in
early clinical trials.
J. Biedler (New York) reviewed the evidence that
membrane alterations are important in conferring
drug resistance to multiple natural cytotoxic
compounds following exposure to only one. This
pleiotropic acquired drug resistance (PDR) has long
been known to be associated with the over
production of a 180kD glycoprotein (P180) as a
stable mutational event in suitably treated cell lines.
She reported that in Chinese hamster lung cells a
series of plasma membrane glycoproteins kD 150-
180 can be detected in PDR lines and that these
may be the cause or the consequence of resistance
following drug exposure. She also pointed out that
ganglioside depletion occurred in the cell membrane
and a specific protein of molecular weight around
1OOkD could be demonstrated as depleted in cells
which at the same time acquired the kD 150-180
species. The latter protein(s) also may be related to
the EGF receptor which is of similar molecular
weight. She stopped short of equating the two
proteins and indeed stressed that the human cell
line A431 which is particularly rich in EGF
receptor is not resistant to the relevant cytotoxic
compounds. However, she did stress that high EGF
binding is associated with decreased tumour-
geneicity in the resistant Chinese hamster lung cell
lines on which these experiments were performed.
Drug sensitive clones express few EGF receptors
but this could be due to down-regulation, a
consequence of autocrine TGF production binding
to the receptor.
S.B. Kaye (Glasgow) reviewed evidence that
verapamil as a non-anticancer drug may enhance
the effect of anticancer drugs against resistant
cancers in vitro and in vivo. He pointed out that
more than 18 separate models now exist attesting to
the anti resistance effect of verapamil but that the
latter effect requires a molecular concentration of
verapamil (1-lO 1umol) which is barely achievable in
the clinic. Clinical experiments have been performed
which have taken the verapamil dose to 480mg
daily in man but above this dose cardiovascular
side effects preclude any further dose increment. At
this dose, however, the drug may be present in just
sufficient quantities to have an important effect on
cytotoxic drug handling. The value of this approach
is now being examined in small cell lung cancer.
W. Ross (Florida) reviewed topoisomerase II as the
target enzyme for the action of intercalating
compounds and epipodophyllotoxins. Topoiso-
merase II is a nuclear enzyme and has important578 WORKSHOP ON DRUG RESISTANCE
structural effects on DNA by mediating un-
knotting, relaxing and decatenating functions on
coiled DNA. Importantly the enzyme content is
directly proportional to the chemosensitivity of the
cell to these cytotoxic drugs. This is a most unusual
situation as target enzyme increment in cells is
usually associated with resistance rather than
enhanced sensitivity. There is also some evidence
for drug-induced alteration in quality of topo-
isomerase without quantitative alteration.
Generally, differentiated and resistant cells tend to
diminish their content of topoisomerase II.
A paper on DNA amplification was unfortunately
cancelled at the last moment but the importance of
DNA repair in drug resistance was reviewed by J.J.
Roberts (Royal Marsden) who discussed his work
with cis-platinum resistance in the Walker cell line.
Using resistant and sensitive cell lines he showed
that both cell lines are equally competent in the
excision repair of cis-platinum-induced DNA
damage including any interstrand cross links. They
are also equally able to repair restriction enzyme-
induced double strand breaks in a transfected
plasmid DNA. However the sensitive line is
defective in the ability to replicate DNA on a
damaged template. Walker tumour cells are
unusally sensitive to the effect of difunctional anti-
cancer drugs pointing to the possibility of genetic
acquisition of the above defect. However, most
apparently inherently resistant in vitro lines in fact
exhibit normal degrees of sensitivity and normal
repair mechanisms. The justification for using such
models and doses of anticancer drugs was to some
extent supported by the few clinical data from
human ovarian cancer cells from patients treated
with cis-platinum where the molar concentration of
drug to DNA was of the same order of magnitude
as that obtained in the in vitro studies.
Finally, in a challenging summary of what had
gone before linked to a hypothesis of the way
things should go in future, A.L. Harris (Newcastle)
suggested that we were 'barking up the wrong tree'
by looking at induced resistance in vitro. He
pointed that out that gene amplification is too
specific and late an event to explain primary
tumour resistance and other types of drug
resistance seen in the clinic. He was similarly
dubious about the importance of hypoxia and thiol
mechanisms as useful models for exploring
improvements in anticancer therapy. He pointed
out that normal tissues (including bone marrow)
are actually quite resistant to cytotoxic drugs and
that cancers derived from these tissues are
proportionately so. Therefore the natural state is
one of relative drug resistance. Prof. Harris
described sublines obtained from point mutated
Chinese hamster ovary cells and identified 7 mutant
strains indicating at least 7 genes present in the wild
type strain that seem to code for natural resistance
to a range of anticancer compounds. Experiments
are proceeding to identify and isolate the genes that
code for natural resistance. He then went on to
speculate that in vitro experiments point to the
existence of soluble factors that influence drug
sensitivity or resistance, pointing to the experience
of the relative resistance of tumour spheroids as
opposed to isolated cell suspensions. In the clinic,
undifferentiated cancers are always associated with
poor prognosis, and cell interactions could be
important in mediating drug resistance or
sensitivity. Factors related to cell growth and
proliferation seen in relatively undifferentiated
tumours may also be related to resistance.
Although these tumours may be more susceptible to
chemotherapy they may also be better able to cope
with the damage produced if the enzymes related to
DNA repair are also involved in replication. The
presence of epidermal growth factor receptors in
human breast and bladder cancers seems to
correlate with the degree of tumour invasion,
metastasis formation and even the degree of
differentiation. The receptor occupies a key role for
interactions with tumour growth factors as well as
being related to a known oncogene product at least
on the cytoplasmic domain. The processes regulated
by tumour growth factors may be more relevant to
resistance to treatment than those currently
evaluated by chemical pathways. The fact that
membrane resistance is associated with an increase
in EGF receptors is a possible pointer to an
association between the two events of proliferation
and resistance.
The meeting included a lively debate on the topic
'The Goldie-Coldman model is validated by clinical
experience', with K.D. Swenerton (Vancouver) in
favour of the motion and A. Howell (Manchester)
against. It was defeated heavily.
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